Glaucoma Trial, Recruiting NCT06685211 Sponsor: Stanford University Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT06685211
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older.
  • People who are able to attend all required study visits and follow the study schedule.
  • People who have been diagnosed with primary open-angle glaucoma (including normal tension or low tension types), with vision test results falling within a specific range of severity — not too mild and not too advanced — as measured by a standard visual field test called Humphrey Visual Field 24-2.
  • People whose eye pressure is stable and measures below 18 on standard eye pressure testing.
  • People with two eyes that both meet the study requirements — in that case, the eye with the worse visual field score would be the one entered into the study, or the person may choose, or a random assignment process may be used.
  • People who are able to read and sign a consent form, or who can have the consent form read aloud to them if their vision makes reading difficult.

Who may not be able to join:

  • People who are unable to follow the study procedures or attend follow-up visits.
  • People who have a history of eye herpes zoster (a viral infection affecting the eye).
  • People who are currently taking or need to take acyclovir or related antiviral medications during the study period.
  • People who have cloudiness or reduced clarity of the cornea (the front surface of the eye).
  • People who have uveitis or other inflammatory conditions affecting the eye.
  • People who are taking steroid medications or other medicines that suppress the immune system.
  • People who are currently in another clinical drug trial, or who have been in one in the past 3 months (either eye drops in the study eye or medications taken by mouth or injection).
  • People who are pregnant or breastfeeding.
  • People who have a physical or mental health condition that, in the opinion of the study doctor, could increase the risk of taking part or interfere with study results.
  • People who have an opening in the skull, have had a trepanation procedure, or have a heart or brain pacemaker.
  • People who have metal implants inside the skull, such as surgical clips, coils, brain fluid shunts, or similar devices.
  • People who have any skin damage in the area where study electrodes would be placed.
  • People who are under 18 or who are in a coma.
  • People who have recently had an epileptic seizure.
  • People with uncontrolled high blood pressure (above 160 mmHg) or uncontrolled high eye pressure (above 27 mmHg).
  • People with a current problem with drug or alcohol misuse.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jeffrey L Goldberg, MD PhD, Stanford University

Phone: 650-497-5942

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 July 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Visual Field Index (VFI); Mean Deviation (MD); Pointwise Linear Regression (PLR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov